• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Personalis (PSNL) Reports Higher Sales And Wider Losses, Does The Stock Look Fully Valued?

    Simply Wall St·08/11/2026 00:37:42
    Listen to the news

    How Personalis' latest earnings set the stage for investors

    Personalis (PSNL) released Q2 2026 results on 4 August, with sales of US$22.36 million and a net loss of US$31.68 million. This mix of higher revenue and wider loss is central to how investors may reassess the stock.

    For the first six months of 2026, Personalis reported sales of US$37.83 million and a net loss of US$61.72 million. Basic loss per share from continuing operations was US$0.59 for the period, including US$0.30 in Q2 alone.

    See our latest analysis for Personalis.

    Personalis shares have responded strongly to the Q2 update, with a 1-day share price return of 2.40% and a 7-day share price return of 9.85% helping extend a 90-day share price return of 140.07%. The 1-year total shareholder return of 222.22% points to powerful recent momentum despite a weaker 5-year total shareholder return.

    If you are reassessing Personalis after this earnings release, it can also be useful to look at other healthcare AI opportunities using the Simply Wall St screener for 43 healthcare AI stocks.

    After such a sharp move in Personalis, the stock now trades slightly above the average analyst target. Is the market getting ahead of itself, or is this just cautious pricing for a company that is still posting sizeable losses?

    Most Popular Narrative: 4.5% Overvalued

    At a last close of $14.50 versus a narrative fair value of $13.88, Personalis is framed as slightly ahead of that central valuation anchor.

    Accelerating adoption of NeXT Personal, Personalis' proprietary liquid biopsy MRD test, is demonstrated by rapid increases in both test volumes (59% QoQ) and ordering physicians (>600 and rising). This signals that Personalis is strongly positioned to capture a growing share of the expanding precision medicine and oncology market and is likely to drive meaningful clinical revenue and gross margin expansion post-reimbursement.

    Read the complete narrative. Read the complete narrative.

    Want to see what justifies paying above the current analyst target? The narrative leans heavily on fast top line expansion, richer margins and a future earnings multiple rarely seen outside higher growth sectors. It is worth examining how those moving pieces combine into one fair value number that sits just below today’s price.

    Result: Fair Value of $13.88 (OVERVALUED)

    Have a read of the narrative in full and understand what's behind the forecasts.

    However, investors in Personalis still face key risks, including potential delays or limits in Medicare reimbursement and ongoing high cash usage that could eventually require fresh capital.

    Find out about the key risks to this Personalis narrative.

    Next Steps

    This mix of enthusiasm and caution around Personalis can be hard to balance, so act quickly and review the underlying numbers yourself to decide where you stand. To see both sides laid out clearly, start with the 1 key reward and 3 important warning signs.

    Looking for more investment ideas beyond Personalis?

    If you stop at Personalis, you risk missing other opportunities that could fit your approach even better, so give yourself options and review a few focused shortlists.

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.